BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Aug. 27, 2024 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. (“Bolt” or “the Company”) (NASDAQ: BOLT) for violations of §§10(b) and 20(a) of the Securities…